---
layout: post
title: "Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization; Guidance for Industry; Correction"
date: 2026-02-05 18:53:21 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-01836
original_published: 2024-01-31 00:00:00 +0000
significance: 8.00
---

# Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization; Guidance for Industry; Correction

**Published:** February 05, 2026 18:53 UTC
**Source:** Federal Register
**Original Published:** January 31, 2024 00:00 UTC
**Document Number:** 2024-01836

## Summary

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on December 21, 2023. The document announced the availability of a final guidance for industry entitled "Development of Monoclonal Antibody Products Targeting SARS- CoV-2 for Emergency Use Authorization." The document was published with an incorrect docket number. This document corrects that error.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/01/31/2024-01836/development-of-monoclonal-antibody-products-targeting-sars-cov-2-for-emergency-use-authorization)
- API: https://www.federalregister.gov/api/v1/documents/2024-01836

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
